These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37516904)

  • 41. [Epidemiology of hallucinogenic drug use in the Netherlands].
    van Laar MW; van Miltenburg CJA
    Tijdschr Psychiatr; 2020; 62(8):684-692. PubMed ID: 32816297
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Psychedelics and Psychotherapy.
    Nayak S; Johnson MW
    Pharmacopsychiatry; 2021 Jul; 54(4):167-175. PubMed ID: 33285578
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tripping outside the lines: lessons from observational studies of combination psychedelic use beyond regulated clinical contexts.
    Kratina S; Mayo LM
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):541-545. PubMed ID: 37734058
    [No Abstract]   [Full Text] [Related]  

  • 44. Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
    Ryan RS; Copello A; Fox AP
    BMC Psychiatry; 2023 Mar; 23(1):160. PubMed ID: 36918852
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry.
    Barber GS; Dike CC
    Psychiatr Serv; 2023 Aug; 74(8):838-846. PubMed ID: 36987705
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.
    Palmer M; Maynard OM
    Harm Reduct J; 2022 Jul; 19(1):81. PubMed ID: 35871679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.
    Yaden DB; Berghella AP; Hendricks PS; Yaden ME; Levine M; Rohde JS; Nayak S; Johnson MW; Garcia-Romeu A
    Pharmacol Res; 2024 Jan; 199():106998. PubMed ID: 38029805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders.
    Harding F; Seynaeve M; Keeler J; Himmerich H; Treasure J; Kan C
    J Integr Neurosci; 2021 Sep; 20(3):551-560. PubMed ID: 34645088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Psychedelics to Relieve Psychological Suffering Associated with a Life-Threatening Diagnosis: Time for a Canadian Policy Discussion.
    Kratina S; Lo C; Strike C; Schwartz R; Rush B
    Healthc Policy; 2023 May; 18(4):134-142. PubMed ID: 37486818
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
    Sharma R; Batchelor R; Sin J
    J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contextual Parameters Associated with Positive and Negative Mental Health in Recreational Psychedelic Users.
    St Arnaud KO; Sharpe D
    J Psychoactive Drugs; 2023; 55(1):30-39. PubMed ID: 35156542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Addiction specialists' attitudes toward psychedelics: A National Survey.
    Kim A; Suzuki J
    Am J Addict; 2023 Nov; 32(6):606-609. PubMed ID: 37550848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample.
    Kvam TM; Uthaug MV; Andersen KAA; Refsum BB; Tunstad PA; Stewart LH; Jacobsen HB; Grønnerød C
    Front Psychiatry; 2023; 14():1287196. PubMed ID: 38025484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.
    Barnett BS; Greer GR
    J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.